$INT 🇸🇪

Intellego Technologies AB Q2 2025 Interim Report

Main Financial Indicators (Q2 2025 vs. Q2 2024):

Net sales: 217 million SEK (previous year: 55 million SEK) – approximately 300% increase.

Operating result: 154 million SEK (21 million SEK).

Profit after tax: 112 million SEK (13 million SEK).

Earnings per share (undiluted): 3.75 SEK (0.49 SEK).

Cash flow from operating activities: 67 million SEK (10 million SEK).

Cash balance at the end of the period: Approximately 100 million SEK.

First Half of the Year (H1 2025 vs. H1 2024):

Net sales: 418 million SEK (132 million SEK) – approximately 216% increase.

Profit after tax: 206 million SEK (49 million SEK).

Earnings per share: 6.94 SEK (1.83 SEK).

Return on equity: 50% (previous year: 25%).

CEO Claes Lindahl’s comment: “We are continuing the year with record revenue and profit and we are not slowing down. We saw significant growth in revenue, profit, and cash conversion. This happened thanks to our innovative products and our close collaborations with customers such as Henkel and Likang. Our efforts to shorten payment periods have started to show results and will continue during the year. Our sales are accelerating in all business areas; this is thanks to our improved sales efforts, the increase in the recognition of our brand, and new regulations (for example the FDA’s regulation of UV disinfection devices in the U.S.). In addition, we are applying higher prices in new application areas.

Because of our growth, we are raising our 2025 targets: Revenue >700 million SEK (previous: 265 million), EBIT >400 million SEK (previous: 102 million) – this means a 164% increase in revenue and a 292% increase in EBIT on a yearly basis.

In Q2, we allocated about 10 million SEK to partnership investments; these will significantly improve our financial results in the short and long term. Increasing cash generation will be used for expansion and debt payments. Our disinfection business will benefit from new market standards and regulations. Management and the board are reviewing our 3–5 year targets; we will revise them during the year.”